Brainscape's Knowledge GenomeTM

Browse over 1 million classes created by top students, professors, publishers, and experts.


See full index

NCCN > HCL > Flashcards

HCL Flashcards

1
Q

Typical immunophenotype for cHCL:

A

CD5-, CD10-, CD11c+, CD20+ (bright), CD22+, CD25+, CD103+, CD123+, cyclin D1+, annexin A1+, and CD200+ (bright)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
2
Q

Immunophenotype for HCLv (ICC)/SBLPN (WHO5):

A

CD25-, CD123-, annexin A1-, and negative for BRAF V600E mutations

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
3
Q

HCLv (ICC)/SBLPN (WHO5) and IGHV4-34–mutant HCL often show mutations in

A

MAP2K1

IGHV4-34 rearrangements: poor prognosis

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
4
Q

Indications for treatment:

A
  • Systemic symptoms
  • Unexplained weight loss (>10% within prior 6 months)
  • Excessive fatigue
  • Recurrent infection
  • Hemoglobin <11 g/dL
  • Platelets <100,000/mcL
  • Absolute neutrophil count (ANC) <1000/mcL
  • Symptomatic organomegaly
  • Progressive lymphocytosis or lymphadenopathy
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
5
Q

Preferred Regimens for Initial therapy

A

Purine analogs
* Cladribine ± rituximab
* Pentostatin

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
6
Q

Considered for patients who are unable to tolerate purine analogs including frail patients and those with active infection

A

Vemurafenib ± anti-CD20 monoclonal antibody (mAb)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
7
Q

BRAF inhibitor

A
  • Vemurafenib
  • Dabrafenib
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
8
Q

Preferred Regimens for R/R Less than complete
response after initial treatment OR Relapse < 2 years

A
  • Clinical trial
  • Dabrafenib + trametinib (if not previously treated with BRAF inhibitor)
  • Vemurafenib ± rituximab (if not previously given)
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
9
Q

Preferred Regimens for R/R ≥2 years

A
  • Retreatment with initial purine analog + rituximab
  • Alternative purine analog + rituximab
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
10
Q

Considered for patients with disease resistant to BRAF inhibitor therapy

A

Venetoclax ± rituximab

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
11
Q

TRUE OR FALSE

Standard-dose purine analogs should not be administered to patients with active life-threatening or chronic infection.

A

TRUE

Standard-dose purine analogs should not be administered to patients with active life-threatening or chronic infection.

Treat active infection prior to initiating treatment with standard-dose purine analogs.

If it is not possible to control infection, consider initiating treatment with low-dose pentostatin before using standard-dose purine analogs to secure a durable response.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
12
Q

HCL RESPONSE CRITERIA

Complete response (CR)

A

Near normalization of peripheral blood counts:
* Hemoglobin >11 g/dL (without transfusion)
* Platelets >100,000/mcL
* ANC >1500/mcL.
* Regression of splenomegaly on physical examination.
* Absence of morphologic evidence of HCL on both the peripheral blood smear and the bone marrow examination.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
13
Q

HCL RESPONSE CRITERIA

Partial response (PR)

A

Near normalization of the peripheral blood count (as in CR) with a minimum of 50% improvement in
organomegaly and bone marrow biopsy infiltration with HCL.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
14
Q

HCL RESPONSE CRITERIA

Stable disease (SD)

A

Patients whose disease has not met the criteria for an objective remission after therapy are considered to have SD.

SD is not an acceptable response.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
15
Q

HCL RESPONSE CRITERIA

Progressive disease (PD)

A

Patients who have an increase in symptoms related to disease, a 25% increase in organomegaly, or a 25% decline in their hematologic parameters

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
16
Q

HCL RESPONSE CRITERIA

Relapse

A

Reappearance of HCL in the peripheral blood, the bone marrow biopsy, or both by morphologic stains in the absence of hematologic relapse

Hematologic relapse is defined as reappearance of cytopenia(s) below the thresholds defined above for CR and PR.

No treatment is necessarily needed in case of morphologic relapse, treatment decisions for a hematologic relapse are based on several parameters (eg, hematologic parameters warranting intervention, reoccurrence of disease-related symptoms).

17
Q

In patients treated with cladribine, evaluation should not be done before _____ months after therapy.

A

4 months

18
Q

In patients being treated with pentostatin, the bone marrow can be evaluated

A

After the blood counts have nearly normalized and the physical examination shows no splenomegaly

19
Q

Duraion of herpes and pneumocystis jirovecii pneumonia (PJP) virus prophylaxis

A

Minimum of 3 months and until CD4+ T-cell counts ≥200 cells/μL

20
Q

Hairy cell leukemia (HCL) is a rare type of indolent B-cell leukemia comprising about ______ % of all lymphoid leukemias.

A

2%

21
Q

Symptoms of HCL

A

Fatigue and weakness, and most patients will present with splenomegaly (symptomatic or asymptomatic) and/or hepatomegaly, pancytopenia, and uncommonly peripheral lymphadenopathy

22
Q

Morphology of HCL

A
  • Small to medium in size, and show a round, oval, or indented nucleus with a well-defined nuclear border.
  • Cytoplasm with prominent hair-like projections of the cytoplasmic membrane
  • Increased reticulin fibrosis, which frequently results in a “dry” tap
23
Q

New name of HCLv

A

Splenic Bcell lymphoma/leukemia with prominent nucleoli (SBLPN)

More aggressive disease course and may not respond to standard HCL therapies

24
Q

TRUE OR FALSE

Unmutated IGHV may serve as a prognostic marker for poorer outcomes with conventional
therapies

A

TRUE

Unmutated IGHV may serve as a prognostic marker for poorer outcomes with conventional
therapies

Since it is associated with primary refractoriness to purine analog monotherapy, more rapid disease progression, and poor survival

25
Q

Mutation identified in the majority of patients with cHCL and is now regarded as the main source of pathogenesis

A

BRAF V600E kinase-activating mutation

HCLv (ICC)/SBLPN (WHO5) and B-cell lymphoproliferative neoplasms with a cHCL phenotype expressing IGHV4-34 rearrangement lack BRAF V600E mutation

26
Q

TRUE OR FALSE

At the present time, there are no established treatment options for the optimal frontline or subsequent treatment of patients with HCLv
(ICC)/SBLPN (WHO5).

A

TRUE

At the present time, there are no established treatment options for the optimal frontline or subsequent treatment of patients with HCLv
(ICC)/SBLPN (WHO5).

27
Q

TRUE OR FALSE

IV cladribine was associated with a lower rate of viral infections and mucositis despite having a higher rate of neutropenia

A

FALSE

Subcutaneous cladribine was associated with a lower rate of viral infections and mucositis despite having a higher rate of neutropenia

28
Q

(CD22-directed recombinant immunotoxin)
was initially approved for the treatment of relapsed or refractory HCL but currently no longer
recommended

A

Moxetumomab pasudotox

NCCN (13 decks)

Brainscape helps you reach your goals faster, through stronger study habits.
© 2024 Bold Learning Solutions. Terms and Conditions